Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

Recruiting now · Phase 1/Phase 2

Conditions studied: Aggressive NK Cell Leukemia

In brief

This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.

Key facts

Study ID

NCT05863234

Run by

Hiroshima University Hospital

People needed

7

Starts

2023-09-21

Expected to finish

2026-03-31

Last updated by the study team

2025-04-30

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with ANKL (regardless of whether the disease is first or recurrent) based on diagnostic criteria developed with reference to the World Health Organization (WHO) 4th edition (2017) criteria.

You may not qualify if…

• Patients eligible to receive chemotherapy as treatment for ANKL

Where it is running

• Hiroshima University Hospital — Hiroshima, Hiroshima, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.